A. Pedersen

发表

External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts.

N. Brünner, C. Sweep, G. Brugal, 1998, British Journal of Cancer.

Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer

H. Nielsen, N. Brünner, I. Christensen, 1999, British Journal of Cancer.

Leucocyte-derived bioactive substances in fresh frozen plasma.

H. Nielsen, N. Brünner, A. N. Pedersen, 1997, British journal of anaesthesia.

Prestorage leukofiltration of whole blood and SAGM blood prevents extracellular bioactive substance accumulation

H. Nielsen, A. N. Pedersen, E. Dybkjær, 1999, Inflammation Research.

Reduction of bioactive substances in stored donor blood: prestorage versus bedside leucofiltration

H. Nielsen, A. N. Pedersen, T. Mynster, 1999, European journal of haematology.

Prestorage leukocyte filtration may reduce leukocyte-derived bioactive substance accumulation in patients operated for burn trauma.

H. Nielsen, A. N. Pedersen, E. Dybkjær, 1999, Burns : journal of the International Society for Burn Injuries.

Effect of heating on extracellular bioactive substances in stored human blood: in vitro study.

H. Nielsen, A. N. Pedersen, T. Mynster, 1997, The Journal of trauma.

Leucocyte and platelet‐derived bioactive substances in stored blood: effect of prestorage leucocyte filtration

H. Nielsen, N. Brünner, A. N. Pedersen, 1997, European journal of haematology.

Time‐dependent, spontaneous release of white cell‐ and platelet‐derived bioactive substances from stored human blood

H. Nielsen, N. Brünner, H. Kehlet, 1996, Transfusion.

Leucocyte and platelet derived bioactive substances in stored standard platelet concentrates

H. Nielsen, N. Brünner, A. N. Pedersen, 1996, European journal of haematology.

Relationship of nm23 to proteolytic factors, proliferation and motility in breast cancer tissues and cell lines.

N. Brünner, K. Geisinger, A. N. Pedersen, 1998, British Journal of Cancer.

The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis.

N. Brünner, I. Christensen, H. Pappot, 2006, Lung cancer.

Plasminogen activator inhibitor type 1 in cancer: therapeutic and prognostic implications.

N. Brünner, H. Pappot, H. Gårdsvoll, 1995, Biological chemistry Hoppe-Seyler.

ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients.

H. Nielsen, N. Brünner, K. Danø, 1997, Clinical chemistry.

The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA.

N. Brünner, G. Clark, K. Danø, 1997, Journal of immunological methods.

The Urokinase Plasminogen Activation System in Breast Cancer

N. Brünner, B. Nielsen, R. Stephens, 1999 .

Immunoassays of urokinase (uPA) and its type-1 inhibitor (PAI-1) in detergent extracts of breast cancer tissue.

N. Brünner, H. Mouridsen, A. N. Pedersen, 2003, European journal of cancer.

The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival.

N. Brünner, I. Christensen, P. Briand, 2000, Cancer research.

Determination of the complex between urokinase and its type-1 inhibitor in plasma from healthy donors and breast cancer patients.

H. Nielsen, N. Brünner, D. Jarosz, 1999, Clinical chemistry.

Loss of ELISA specificity due to biotinylation of monoclonal antibodies.

H. Nielsen, N. Brünner, K. Danø, 2000, Journal of immunological methods.

Tumor Tissue Concentrations of the Proteinase Inhibitors Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and Plasminogen Activator Inhibitor Type 1 (PAI-1) Are Complementary in Determining Prognosis in Primary Breast Cancer *

N. Brünner, J. Foekens, I. Christensen, 2003, Molecular & Cellular Proteomics.